Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Professional, scientific, and technical services tags : Disease save search
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
IPSC | $3.06 2.86% 2.78% 110K
|
Professional, Scientific, and T...
|
| O: 3.39%
H: 11.53%
C: 2.02%
disease million pipeline acquisition expansion therapeutics
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K
|
Professional, Scientific, and T...
|
| O: -1.5%
H: 0.0%
C: -2.29%
brtx-100 disease trial
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
ABOS | $3.14 -0.63% -0.64% 310K
|
Professional, Scientific, and T...
|
| O: 4.19%
H: 2.01%
C: -3.52%
disease alzheimer’s treatment pharmaceuticals
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
Published: 2024-03-19 (Crawled : 13:00) - globenewswire.com
CNTB | $1.49 -1.97% -2.01% 32K
|
Professional, Scientific, and T...
|
| O: 2.42%
H: 0.0%
C: -5.51%
conference disease biopharma
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -4.66%
H: 6.67%
C: 3.56%
gt-0228 conference disease treatment parkinson’s therapeutics
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
Published: 2024-03-01 (Crawled : 20:00) - globenewswire.com
RXRX | $7.36 -0.54% -0.54% 3.9M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
day rare disease
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-02-27 (Crawled : 19:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 0.22%
H: 3.45%
C: -3.88%
gt-0228 disease parkinson’s trial therapeutics therapy
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
Published: 2024-02-14 (Crawled : 18:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 5.32%
C: 4.88%
disease update parkinson’s therapeutics
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Published: 2024-02-06 (Crawled : 15:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -0.46%
H: 7.55%
C: 2.29%
gt-0228 disease update parkinson’s
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Published: 2024-02-06 (Crawled : 13:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -0.46%
H: 7.55%
C: 2.29%
gt-0228 disease parkinson’s
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-02-05 (Crawled : 12:30) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K
|
Professional, Scientific, and T...
|
| O: 14.64%
H: 14.33%
C: 7.48%
brtx-100 disease study
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
Published: 2024-01-29 (Crawled : 15:30) - biospace.com/
CYTH | $1.19 -0.83% -0.84% 57K
|
Professional, Scientific, and T...
|
| O: 6.43%
H: 1.58%
C: -2.75%
patent disease alzheimer’s treatment application therapeutics
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
Published: 2023-12-18 (Crawled : 23:00) - biospace.com/
CYTH | $1.19 -0.83% -0.84% 57K
|
Professional, Scientific, and T...
|
| O: 8.03%
H: 0.54%
C: -6.76%
trappsol fda disease positive treatment meeting program therapeutics
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
|
| O: 3.09%
H: 5.08%
C: 0.0%
first disease kidney dialysis trial therapeutics
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219
Published: 2023-12-11 (Crawled : 16:00) - biospace.com/
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -24.51%
H: 1.49%
C: -7.69%
alent-101 first disease ongoing bmf-219 study
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting
Published: 2023-12-11 (Crawled : 14:30) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -24.51%
H: 1.49%
C: -7.69%
alent-101 first disease ongoing bmf-219 meeting leukemia study
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Published: 2023-12-08 (Crawled : 14:00) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: 3.59%
H: 10.15%
C: 8.48%
alent-111 disease congress control world presentation treatment ongoing bmf-219 diabetes cardiovascular insulin study
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Published: 2023-12-07 (Crawled : 14:30) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 10.89%
C: -18.54%
alent-111 disease congress world ongoing bmf-219 diabetes cardiovascular results insulin study
Biomea Fusion Abstract Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
Published: 2023-11-16 (Crawled : 15:00) - biospace.com/
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -0.11%
H: 6.94%
C: 0.32%
disease six congress world one diabetes cardiovascular insulin
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
Published: 2023-11-16 (Crawled : 13:30) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -0.11%
H: 6.94%
C: 0.32%
bmf-219 disease six congress world one diabetes cardiovascular insulin
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.